BGI Genomics

BGI Genomics is a Chinese genomics and molecular-diagnostics company associated with the broader BGI Group. Its business centers on the application of high-throughput DNA sequencing, bioinformatics, and related laboratory technologies to clinical, research, and public-health use cases. The company operates from Shenzhen and serves customers and institutional partners in China as well as international markets. The brand is part of the expansion of genomics from specialist research into routine laboratory and healthcare workflows. Its service portfolio has included reproductive-health testing, oncology-related molecular testing, infectious-disease testing, genetic disease analysis, sequencing services, and bioinformatics support. These offerings are used by hospitals, clinical laboratories, research organizations, pharmaceutical and biotechnology companies, public-health bodies, and other institutions. The precise availability of individual tests and services varies by jurisdiction, regulatory status, and local laboratory arrangements. BGI Genomics is closely connected to BGI's wider sequencing, instrument, laboratory, and research ecosystem, but it is distinct from the group's research and instrument-focused activities. The company has developed a commercial model based on combining laboratory capacity, sequencing platforms, data interpretation, and specialized application expertise rather than selling only a single consumer-facing product. This allows it to participate in both contract sequencing and more standardized diagnostic services. A major area of public visibility has been non-invasive prenatal testing, which analyzes cell-free fetal DNA in maternal blood to screen for selected chromosomal abnormalities. The company has also pursued oncology testing and other clinical applications in which genomic information can support diagnosis, risk assessment, treatment selection, or disease monitoring. In research and industrial settings, sequencing and computational analysis can support population studies, agricultural genomics, drug development, and biomarker discovery. The company operates in a sensitive sector in which clinical validity, laboratory quality, personal-data protection, genetic-data governance, and regulatory approval are central to its reputation and commercial access. As a result, BGI Genomics' position is shaped not only by sequencing capability and price, but also by the requirements of hospitals, regulators, research sponsors, and patients. Its broader corporate association with BGI has also made the brand part of international discussions concerning genomic-data governance and the cross-border use of biological information. Publicly available reference material supplied for this entry describes BGI Genomics as a Chinese biotechnology company and a provider of gene-sequencing and bioinformatics services. The available material does not establish a complete chronology of incorporation, leadership, product launches, or current geographic revenue mix; those fields are therefore kept conservative.

BGI Genomics developed within the broader expansion of BGI from a genomics research organization into a diversified life-science group. The supplied reference material identifies the company as Chinese and emphasizes its role in gene sequencing and bioinformatics, but it does not provide a reliable dated corporate history. Accordingly, the early incorporation details, founder attribution, and exact relationship between the operating company and the wider BGI organization are not stated here as settled facts. The company's business model reflects the maturation of next-generation sequencing. Rather than limiting genomics to academic projects, BGI Genomics applies sequencing and computational analysis to service workflows for hospitals, laboratories, researchers, pharmaceutical and biotechnology companies, agriculture-related programs, and public-health institutions. This application-oriented model includes both laboratory processing and interpretation, allowing customers to obtain genomic data and analytical support without necessarily building a complete internal sequencing operation. Clinical testing became an important area of activity as sequencing technologies moved into reproductive health, hereditary disease, oncology, and infectious disease applications. Non-invasive prenatal screening is a prominent example of this transition: the approach uses maternal blood samples and cell-free DNA to assess the likelihood of selected chromosomal conditions. Other clinical services use genomic or molecular information to support the investigation of tumors, inherited disorders, or pathogens. Product names, regulatory permissions, and clinical indications can differ by market, so the company’s portfolio should not be treated as identical across countries. In parallel, BGI Genomics has supported research and industrial genomics. Sequencing and bioinformatics services can be used in population studies, biomarker research, drug-development programs, agricultural and animal genomics, and other projects requiring large-scale biological-data processing. These activities place the company at the intersection of laboratory operations, computing, data interpretation, and specialized scientific consulting. The company’s development has also occurred amid heightened scrutiny of genetic information. Genomic-service providers must manage sample custody, informed consent, data security, cross-border transfers, clinical quality, and compliance with applicable medical-device and laboratory regulations. BGI Genomics’ association with the wider BGI ecosystem has increased its visibility in debates about the governance of genomic data and international research collaboration. Those debates are distinct from a finding that any particular service or transaction was improper; no specific scandal is documented in the supplied material. The available source set is too limited to support a reliable year-by-year account of incorporation, public listing, management changes, major campaigns, or product-generation history. Further verification against corporate filings, regulatory records, and authoritative company or exchange disclosures would be required for a fully dated corporate chronology.

• Yang Huanming, Yu Jun, Wang Jian and others proposed a strategic vision in Zhangjiajie for China to participate in the Human Genome Project.

• BGI founded at 9:09 a.m., dedicated to the Human Genome Project.

• Agreement signed to launch the Chinese super hybrid rice genome project.

• Working draft of the Human Genome Project completed.

• Science published the Chinese rice (indica) genome working draft as a cover article.

• BGI first in China to decode four SARS virus full genome sequences.

• BGI donated 300,000 SARS virus diagnostic kits to national SARS prevention headquarters.

• Silkworm genome paper published in Science; chicken genome research published as cover article in Nature.

• After Indian Ocean tsunami, BGI Fangrui sent DNA identification team to Thailand.

• Fine map of rice genome completed.

• International HapMap Project, with BGI leading Chinese consortium contributing 10%, published in Nature.

• First International Conference on Genomics held in Hangzhou.

• Shenzhen BGI Research Institute (now BGI Research) established.

• BGI participated in Wenchuan earthquake post-disaster reconstruction and disease monitoring.

• BGI completed giant panda genome sequencing.

• First Asian personal genome map ("Yanhuang No. 1") published as cover article in Nature.

• Human gut microbiome research published as cover article in Nature.

• Tibetan genome research published in Science.

• 1000 Genomes Project results published as cover article in Nature.

• BGI decoded the pathogen genome of the German E. coli outbreak and published in NEJM.

• 1000 Genomes Project consortium published integrated map of human genomic variation based on 1,092 individuals in Nature.

• BGI NIFTY became world's first second-generation gene sequencing test approved by China FDA.

• BGI and partners developed Ebola virus nucleic acid detection reagent.

• BGI and scientists from over 20 countries completed large avian genome project, 28 papers published.

A genomics application and laboratory-services provider connecting high-throughput sequencing and bioinformatics with clinical, research, and public-health use cases.

• Clinical genetic testing

  Non-invasive prenatal screening

  A maternal-blood screening service based on cell-free fetal DNA. It is designed to estimate the likelihood of selected chromosomal abnormalities without an invasive sampling procedure. The exact conditions covered, clinical pathway, and regulatory status depend on the market and the applicable laboratory and medical regulations.

• Molecular diagnostics

  Oncology-related genetic testing

  Sequencing and molecular-analysis services intended for cancer-related applications, which may include tumor profiling, biomarker analysis, hereditary cancer assessment, or other forms of genomic investigation. The clinical use and reporting scope vary by test, specimen type, and jurisdiction.

• Research genomics

  Sequencing and bioinformatics services

  Laboratory sequencing combined with computational processing, quality control, data analysis, and interpretation. These services support academic and translational research, pharmaceutical and biotechnology programs, population studies, agricultural genomics, and other projects that require genomic data without a fully internal sequencing and analysis infrastructure.

• 2021

  BGI Group prenatal genetic testing raises data privacy and cross-border regulatory concerns

  In 2021, Reuters reported on genetic data research from BGI Group's NIFTY prenatal test and cooperation with military hospitals, triggering reviews by regulators in multiple countries. BGI denied the claim that it jointly developed the test with the military, saying it complies with privacy laws and has not been asked to provide data for national security purposes. This entry concerns controversy over the group's associated testing business, not a conviction that the listed company stole data.

  Source

• 2020

  BGI Genomics responds to concerns about COVID-19 test kits

  In August 2020, BGI Genomics responded to media concerns regarding a high positive detection rate associated with its COVID-19 test kits. The company stated that the high sensitivity of the tests could produce positive results, and that this characteristic could be useful for epidemic prevention among the general population. The response addressed questions raised in media reports about the positive detection rate of the kits.

  Source

Read more

• 2020.12.23

  Reported2020.12.28

  BGI Genomics wins Shenzhen Mayor Quality Award[8]华大基因荣获深圳市市长质量奖finance.sina.com.cn

  BGI Genomics received the bronze award in the economic category of the Shenzhen Mayor Quality Award at the Shenzhen Quality Conference.

• Unconfirmed

  BGI Genomics starts production at Ethiopia plant[9]华大基因埃塞俄比亚工厂启动生产yicaiglobal.com

  BGI Genomics began production at a new plant in Ethiopia. The facility is intended to help the country reduce reliance on imported COVID-19 testing kits.

• 2020.08.26

  Reported2020.08.26

  BGI Genomics responds to concerns about COVID-19 test kits[7]BGI Genomics responds to concerns about COVID-19 test kitsfinance.sina.com.cn

  BGI Genomics responded to media concerns about a high positive detection rate for its COVID-19 test kits, stating that the high sensitivity of the tests could produce positive results and could be useful for epidemic prevention among the general population.

• 2020.04.25

  Reported2020.04.25

  BGI Genomics reported first-quarter 2020 results[10]华大基因公布2020年一季度业绩finance.sina.com.cn

  BGI Genomics reported first-quarter 2020 revenue of RMB 791 million, up 35.78% year over year, and net profit attributable to shareholders of RMB 140 million, up 42.59%.

• 2020.04.23

  Reported2020.04.23

  Pinduoduo offers COVID-19 nucleic acid test bookings[11]拼多多上线新冠核酸检测预约服务finance.sina.com.cn

  Pinduoduo users could book COVID-19 nucleic acid tests through the platform in nearly 50 cities. BGI Genomics offered the service, alongside other health-check providers.

• 2020.04.23

  Reported2020.04.23

  Pinduoduo and BGI launch COVID-19 test booking service[12]拼多多与华大基因上线新冠核酸检测预约服务tech.sina.com.cn

  Pinduoduo and BGI launched an online appointment service for COVID-19 nucleic acid testing, available in nearly 50 cities.

• 2020.01.30

  Reported2020.01.30

  BGI announces donation of test kits to support epidemic response[13]华大基因宣布捐赠试剂盒支持疫情防控finance.sina.com.cn

  BGI announced a donation of 20,000 test kits to support Hubei's response to the epidemic and said it would work with other companies to donate a further 100,000 kits. The source says the first batch had already reached the Wuhan Red Cross.

• 2019.10.15

  BGI wins Global Corporate Social Responsibility Health Promotion Award[14]华大基因荣获“全球企业社会责任健康促进奖”sc.stock.cnfol.com

  BGI won the Global Corporate Social Responsibility Health Promotion Award at the 2019 Global Corporate Social Responsibility Summit, recognizing its contributions to life-sciences research and global healthcare.

Read more

1. 1BGI Genomics official websitegenomics.cn
2. 2华大简介genomics.cn
3. 3发展历程genomics.cn
4. 4BGI Genomics - Wikidatawikidata.org
5. 5华大基因 - 维基百科zh.wikipedia.org
6. 6BGI Group prenatal genetic testing raises data privacy and cross-border regulatory concernsinvesting.com
7. 7BGI Genomics responds to concerns about COVID-19 test kitsfinance.sina.com.cn
8. 8华大基因荣获深圳市市长质量奖finance.sina.com.cn
9. 9华大基因埃塞俄比亚工厂启动生产yicaiglobal.com
10. 10华大基因公布2020年一季度业绩finance.sina.com.cn
11. 11拼多多上线新冠核酸检测预约服务finance.sina.com.cn
12. 12拼多多与华大基因上线新冠核酸检测预约服务tech.sina.com.cn
13. 13华大基因宣布捐赠试剂盒支持疫情防控finance.sina.com.cn
14. 14华大基因荣获“全球企业社会责任健康促进奖”sc.stock.cnfol.com
15. 15华大基因发布2019年全年财报，实现营收28亿元，生育健康业务占比近半finance.sina.com.cn